Therese Johaug, the celebrated Norwegian cross-country skier, has publicly voiced strong opposition to the burgeoning trend of weight-loss medications, calling for an outright ban. Johaug expressed her concerns on November 14, 2025, citing potential health risks and unfair competitive advantages within sports.
The debate surrounding these drugs-primarily GLP-1 receptor agonists-has intensified in recent months as their popularity surges beyond medical prescriptions for obesity and diabetes,extending into recreational use and athletic circles. Johaug’s stance arrives as Norwegian sports authorities grapple with establishing clear guidelines regarding the use of such substances, with implications for athlete health, fair play, and the integrity of competition. The stakes are high, perhaps reshaping the landscape of professional athletics and public health perceptions of body image.
“I think it’s incredibly dangerous,” Johaug stated, according to reporting by VGTV. “These medicines can have serious side effects, and I’m worried about the long-term consequences for people’s health.It’s also not fair to those who achieve their results through hard work and dedication.”
Johaug’s comments come amid growing scrutiny of the medications’ impact on athletic performance. While not currently prohibited by the World Anti-Doping Agency (WADA), the drugs’ ability to suppress appetite and potentially enhance endurance raises ethical questions about their use in competitive sports. The Norwegian Olympic Committee is currently reviewing the situation and considering potential policy changes.
The athlete’s concerns echo those of medical professionals who caution against the widespread, non-medical use of these powerful drugs. Common side effects include nausea, vomiting, and diarrhea, while longer-term risks are still being studied. The accessibility of these medications through online pharmacies and unregulated channels further exacerbates the concerns.
